glp-1 neuroinflammation Glucagon-like peptide-1 suppresses and improves neural structure Frontiers | GLP-1 receptor agonists
Description
Despite legitimate safety concerns and the lack of FDA (US Food and Drug Administration) approval for their use in type 1 diabetes, SGLT2i are used as adjunctive therapy in individuals with type 1 diabetes [18]
It is important to recognize that microdosing is considered a medical treatment
It also helps identify patterns that might not be obvious otherwise
Before choosing an ODT, it is worth asking: Am I more likely to stay consistent with one weekly treatment or one daily habit
General best practice: Monthly for the first 3 months (especially with GLP-1s to monitor GI side effects and adjust dosing), then every 2-3 months once stable
